For citations:
Chowdhury S., Oudard S., Uemura H., Joniau S., Dearden L., Capone C., van Sanden S., Diels J., Hadaschik B.A. Apalutamide compared with darolutamide for the treatment of non-metastatic castration resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison. Cancer Urology. 2022;18(1):77-89. (In Russ.) https://doi.org/10.17650/1726-9776-2022-18-1-77-89
Email this article 